Loading clinical trials...
Loading clinical trials...
The purpose of this open-label, dose-ranging, exploratory study is to evaluate the safety, tolerability, compliance, mechanism of action and efficacy of QBECO site specific immunomodulation for the in...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Qu Biologics Inc.
NCT06979336 · Ulcerative Colitis
NCT06937086 · Ulcerative Colitis, Obesity or Overweight
NCT07593352 · IBD and Renal Involement, Chronic Kidney Disease, and more
NCT06100289 · Ulcerative Colitis, Crohn's Disease
NCT04844606 · Ulcerative Colitis, Ulcerative Colitis Chronic, and more
University of Alberta
Edmonton, Alberta
GI Research Institute
Vancouver, British Columbia
McMaster University
Hamilton, Ontario
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions